Allergan Plc (AGN)

166.14
NYSE : Health Technology
Prev Close 166.35
Day Low/High 165.68 / 167.05
52 Wk Low/High 114.27 / 197.00
Avg Volume 4.92M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 54.57B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.77%)
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

Let's look closer at the charts and indicators of ABBV.

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.

AbbVie To Acquire Allergan In Transformative Move For Both Companies

AbbVie To Acquire Allergan In Transformative Move For Both Companies

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Allergan Receives FDA Clearance For CoolTone™ Device

Allergan Receives FDA Clearance For CoolTone™ Device

MAGNETIC MUSCLE STIMULATION TECHNOLOGY TO STRENGTHEN, TONE AND FIRM MUSCLES

Wild Week Ahead

The intermediate-term sentiment indicators don’t show too much giddiness -- yet -- but look at all the market has on its plate this week.

FDA Approves BOTOX® (onabotulinumtoxinA) For Pediatric Patients With Upper Limb Spasticity

FDA Approves BOTOX® (onabotulinumtoxinA) For Pediatric Patients With Upper Limb Spasticity

--BOTOX® is the First Neurotoxin Treatment Approved to Treat Pediatric Patients, 2 to 17 Years of Age, with Upper Limb Spasticity--

Aegon Announces Purchase Of Shares To Neutralize 2018 Final Stock Dividend

Aegon Announces Purchase Of Shares To Neutralize 2018 Final Stock Dividend

Aegon will repurchase 32,873,805 common shares to neutralize the dilutive effect of the 2018 final stock dividend.

Ironwood And Allergan Report Positive Topline Data From Phase IIIb Trial Of LINZESS® (linaclotide) In Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood And Allergan Report Positive Topline Data From Phase IIIb Trial Of LINZESS® (linaclotide) In Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and  Allergan plc (NYSE:AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C.

Aegon Bank Successfully Prices Inaugural EUR 500 Million Senior Non-Preferred Notes

Aegon Bank Successfully Prices Inaugural EUR 500 Million Senior Non-Preferred Notes

Today, Aegon Bank priced its inaugural EUR 500 million 5 year Senior Non-Preferred notes with a yield of 0.

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin

Moderna, Six Flags, Chevron and More: 'Mad Money' Lightning Round

Moderna, Six Flags, Chevron and More: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

We're in Bizarro Land: Cramer's 'Mad Money' Recap (Wednesday 6/5/19)

We're in Bizarro Land: Cramer's 'Mad Money' Recap (Wednesday 6/5/19)

Investors should consider recession-proof names in the current environment, Jim Cramer says.

Watch These 9 Companies in a Botox Export Boom Out of South Korea

Watch These 9 Companies in a Botox Export Boom Out of South Korea

South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.

Bas NieuweWeme Appointed As CEO Of Aegon Asset Management

Bas NieuweWeme Appointed As CEO Of Aegon Asset Management

Aegon today announces that Sarah Russell (1962, Australian), member of Aegon's Management Board and Global CEO of Aegon Asset Management, will step down.

Allergan And Gedeon Richter Receive U.S. FDA Approval For Expanded Use Of VRAYLAR® (cariprazine) In The Treatment Of Bipolar Depression

Allergan And Gedeon Richter Receive U.S. FDA Approval For Expanded Use Of VRAYLAR® (cariprazine) In The Treatment Of Bipolar Depression

- New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes -

Allergan Announces Updated Presentation Time At The Bernstein Strategic Decisions Conference

Allergan Announces Updated Presentation Time At The Bernstein Strategic Decisions Conference

DUBLIN, May 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35 th Annual Strategic Decisions Conference in New York, NY.

Allergan To Present At The Jefferies 2019 Healthcare Conference

Allergan To Present At The Jefferies 2019 Healthcare Conference

DUBLIN, May 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chief Commercial Officer William Meury will participate in a fireside chat at the Jefferies 2019 Healthcare Conference in New York, NY.

Allergan Expands PLEDGE Clinical Research Program In Diabetic Gastroparesis

Allergan Expands PLEDGE Clinical Research Program In Diabetic Gastroparesis

-- Five PLEDGE studies now active and enrolling patients to evaluate the safety and efficacy of relamorelin (investigational drug) in people with diabetic gastroparesis --

Aegon To Divest Stake In Partnership With Sony Life In Japan

Aegon To Divest Stake In Partnership With Sony Life In Japan

"With the evolving market conditions, we mutually agreed that the future of the variable annuity business in Japan is best served as a wholly-owned part of our longstanding partner Sony Life", said Alex Wynaendts, CEO of Aegon.

China Winners and Losers: Cramer's 'Mad Money' Recap (Thursday 5/16/19)

China Winners and Losers: Cramer's 'Mad Money' Recap (Thursday 5/16/19)

Jim Cramer says Thursday's market action showed us a rally based on good old-fashioned earnings.

Jim Cramer: These 7 True Laggards Have Caught Fire

Jim Cramer: These 7 True Laggards Have Caught Fire

These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.

Allergan To Present At The Bernstein Strategic Decisions Conference

Allergan To Present At The Bernstein Strategic Decisions Conference

DUBLIN, May 16, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35 th Annual Strategic Decisions Conference in New York, NY.

Allergan To Present VRAYLAR® (cariprazine) Data At The American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment To Mental Health

Allergan To Present VRAYLAR® (cariprazine) Data At The American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment To Mental Health

Abstracts will showcase research on VRAYLAR, including a focus on an investigational use for the treatment of bipolar depression

PatientFi® Announces Study Partnership With Allergan

PatientFi® Announces Study Partnership With Allergan

PatientFi, LLC, a leading financial technology company that partners with medical practices to offer patients accessible financing plans for elective procedures, is pleased to announce its partnership with Allergan plc on a year-long market research study...

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.

Allergan To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

Allergan To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

DUBLIN, May 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada.

TheStreet Quant Rating: C (Hold)